Table of Contents
Chemotherapy Research and Practice
Volume 2010, Article ID 524629, 8 pages
Research Article

Does Type of Tumor Histology Impact Survival among Patients with Stage IIIB/IV Non-Small Cell Lung Cancer Treated with First-Line Doublet Chemotherapy?

1i3 Innovus, Medford, MA 02155, USA
2Global Health Outcomes, Lilly Corporate Center, Eli Lilly and Company, DC6831, Indianapolis, IN 46285, USA
3Boston Health Economics, Inc., Waltham, MA 02451, USA
4Institute for Clinical Evaluative Sciences, Toronto, ON, Canada M4N 3M5

Received 10 November 2009; Revised 17 May 2010; Accepted 16 June 2010

Academic Editor: Nagahiro Saijo

Copyright © 2010 Karen M. Clements et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Chemotherapy regimens may have differential efficacy by histology in nonsmall cell lung cancer (NSCLC). We examined the impact of histology on survival of patients ( ,644) with stage IIIB/IV NSCLC who received first-line cisplatin/carboplatin plus gemcitabine (C/C+G) and cisplatin/carboplatin plus a taxane (C/C+T) identified retrospectively in the SEER cancer registry (1997–2002). Patients with squamous and nonsquamous cell carcinoma survived 8.5 months and 8.1 months, respectively ( ). No statistically significant difference was observed in survival between C/C+G and C/C+T in both histologies. Adjusting for clinical and demographic characteristics, the effect of treatment regimen on survival did not differ by histology (P for interaction ). There was no statistically significant difference in hazard of death by histology in both groups. These results contrast the predictive role of histology and improved survival outcomes observed for cisplatin-pemetrexed regimens in advanced nonsquamous NSCLC.